Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

0.8049
-0.0390-4.62%
Post-market: 0.82000.0151+1.88%19:26 EDT
Volume:962.44K
Turnover:792.63K
Market Cap:77.12M
PE:-0.84
High:0.8600
Open:0.8300
Low:0.8005
Close:0.8439
Loading ...

Immunic Begins Underwritten Public Offering

MT Newswires Live
·
29 May

BUZZ-Immunic slides on planned equity raise

Reuters
·
29 May

Immunic announces offering of warrants to purchase common stock

TIPRANKS
·
29 May

Immunic, Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
29 May

Immunic Price Target Cut to $5.00/Share From $6.00 by B. Riley Securities

Dow Jones
·
23 May

Immunic price target lowered to $5 from $6 at B. Riley

TIPRANKS
·
23 May

B. Riley Cuts Price Target on Immunic to $5 From $6, Keeps Buy Rating

MT Newswires Live
·
23 May

Immunic Inc : B. Riley Cuts Target Price to $5 From $6

THOMSON REUTERS
·
23 May

Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential

TIPRANKS
·
16 May

Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating

TIPRANKS
·
16 May

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Immunic (IMUX) and Biogen (BIIB)

TIPRANKS
·
06 May

Immunic Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
02 May

Immunic Inc. to Showcase Clinical Trial Supply Chain Expertise at Clinical Trial Supply Forum 2025

Reuters
·
02 May

Immunic to Participate in Scientific and Industry Conferences in May

PR Newswire
·
02 May

Immunic Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
01 May

Immunic price target raised to $22 from $19 at Brookline

TIPRANKS
·
01 May

BRIEF-Immunic Announces Vidofludimus Calcium Reduced Risk Of Disability Worsening By 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 Calliper Trial

Reuters
·
30 Apr

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
30 Apr

Immunic Inc - 20% Reduction in Disability Worsening Events in Study Population

THOMSON REUTERS
·
30 Apr

Immunic Inc - Favorable Safety Profile Confirmed, No New Safety Signals

THOMSON REUTERS
·
30 Apr